BioOutsource To Open New Biosimilar Center of Excellence

News
Article

BioOutsource will open a new Biosimilar Center of Excellence in Scotland.

BioOutsource, a leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, will open a new Biosimilar Center of Excellence in Glasgow. The new facility will double the company’s capacity for the analysis of biosimilar monoclonal antibodies.

The Biosimilar Center of Excellence is located on the West of Scotland Science Park in Glasgow, adjacent to the existing BioOutsource facility. The new operation will consist of approximately 40 laboratory and R&D scientists creating an estimated 20 new jobs.

Source: BioOutsource

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

CordenPharma and Viking Therapeutics to Partner for Integrated Supply of GLP-1s

Patrick Lavery
March 13th 2025
Article

The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves First Generics of Rivaroxaban Tablets

Patrick Lavery
March 12th 2025
Article

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.

Drug Solutions Podcast: The Biosimilars Landscape

Drug Solutions Podcast: The Biosimilars Landscape

Feliza Mirasol
January 31st 2024
Podcast

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Stäubli Robotics Previews World’s First Cleanroom Mobile Robot for INTERPHEX Display

Patrick Lavery
March 11th 2025
Article

Sterimove will make its North American debut at the April 1–3, 2025 event.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Noramco Group Establishes Sterile Injectable Manufacturing Capabilities with $25 Million Investment

Patrick Lavery
March 10th 2025
Article

The investment is intended for the Halo Pharma facility in Whippany, NJ, and aims to help relieve capacity shortages in the injectable supply chain in the United States.